Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 135 of 6351
-
New drug cocktail shows promise against deadly thyroid cancer before surgery
Disease control OngoingThis phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sendin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
Disease control OngoingStudy CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug shows promise against brain tumors
Disease control OngoingThis is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed o…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could an amino acid shorten sickle cell pain crises?
Symptom relief CompletedThe trial is designed to test intravenous (IV) arginine therapy in children with sickle cell disease (SCD) and vaso-occlusive painful episodes (VOE) to further knowledge on efficacy and safety of this orphan drug.
Phase 3 • Sponsor: Claudia R. Morris • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Stem cells may help babies with spina bifida walk better
Disease control Recruiting nowSpina bifida, or myelomeningocele (MMC), is a birth defect that results in paralysis, excess fluid on the brain (hydrocephalus), and impaired ability to urinate and have bowel movements normally. In a previous study (the MOMS trial), surgery before birth (in-utero/fetal surgery) …
Phase 1/2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a psychedelic drug lift depression that won't budge?
Disease control CompletedA single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive disorder. The primary objective is to evaluate feasibi…
Phase 2 • Sponsor: King's College London • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Weight-Loss drug semaglutide shows promise for heart failure with diabetes
Disease control CompletedThis study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Radioactive bullet targets tough prostate cancer in major trial
Disease control OngoingThe purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) particip…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can immunotherapy outperform chemotherapy for lung cancer?
Disease control CompletedThe pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients
Sponsor: Myung-Ju Ahn • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Promising Gene-Targeting drug for ALS enters final trial phase
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can an antibody slow Alzheimer's? a new trial seeks answers
Disease control CompletedThe purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Promising new combo therapy for advanced prostate cancer enters final testing phase
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a c…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lupus shot shows promise in major trial
Disease control OngoingThe purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a targeted pill keep lung cancer from returning?
Disease control Recruiting nowThis is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex…
Phase 3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Balloon in the aorta could boost CPR success in cardiac arrest
Disease control OngoingThe primary aim of this trial is to assess the efficacy of resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct treatment to advanced cardiovascular life support (ACLS) in patients with out-of-hospital cardiac arrest. Out of hospital cardiac arrest (OH…
Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug zilganersen aims to slow rare brain disease
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a newer hepatitis b drug protect babies while being gentler on their bones?
Disease control Recruiting nowMother-to-child transmission (MTCT) is still the main transmission route of HBV in high-endemic areas, such as China, sub-Saharan Africa, etc. Some infants born of mothers with high HBV DNA load (≥2×10\^5 IU/ml) are still infected with HBV even if these infants receive the combin…
Sponsor: Xingfei Pan • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a common supplement curb stroke damage?
Disease control Completed1. Clarify novel systemic and local inflammatory mechanisms underlying the cross talk between brain and heart ischemic states, 2. Investigate the new aspects of NAC beyond traditional therapy, in cerebral and myocardial ischemic conditions, both in animal models and clinical case…
Phase 3 • Sponsor: Helwan University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted antibody give pancreatic cancer chemo a boost?
Disease control CompletedThis trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT), in combination with ONIVYDE + LV + 5-FU chemother…
Phase 1/2 • Sponsor: XBiotech, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC